|
Market Closed -
Toronto S.E.
22:59:56 14/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 13.38 CAD | -3.39% |
|
-2.55% | +68.94% |
Company Valuation: Satellos Bioscience Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6.794 | 36.73 | 95.65 | 89.3 | 200.8 | - | - |
| Change | - | 440.53% | 160.46% | -6.65% | 124.93% | - | - |
| Enterprise Value (EV) 1 | 6.794 | 36.73 | 46.68 | 89.3 | 163.4 | 81.85 | 13.65 |
| Change | - | 440.53% | 27.11% | 91.29% | 83.04% | -49.92% | -83.32% |
| P/E | - | - | -3.32x | -3.36x | -4.14x | -6.15x | -5.99x |
| PBR | - | - | - | - | 5.67x | 4.46x | - |
| PEG | - | - | - | 0.2x | -0.1x | 0.2x | -2.28x |
| Capitalization / Revenue | - | - | - | - | - | - | 66.9x |
| EV / Revenue | - | - | - | - | - | - | 4.55x |
| EV / EBITDA | - | - | - | -3.38x | -6.54x | -2.95x | -0.49x |
| EV / EBIT | -1.08x | -3.23x | -2.4x | -3.37x | -3.47x | -1.6x | -0.22x |
| EV / FCF | - | - | -2.67x | - | -3.89x | -2.16x | -0.26x |
| FCF Yield | - | - | -37.5% | - | -25.7% | -46.2% | -381% |
| Dividend per Share 3 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 3 | - | - | -3 | -2.354 | -3.234 | -2.175 | -2.232 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 3 |
| EBITDA 1 | - | - | - | -26.46 | -25 | -27.75 | -28 |
| EBIT 1 | -6.268 | -11.38 | -19.45 | -26.46 | -47.09 | -51.03 | -61.51 |
| Net income 1 | -8.368 | -11.69 | -19.65 | -24.87 | -51.27 | -46.97 | -76.52 |
| Net Debt 1 | - | - | -48.97 | - | -37.4 | -119 | -187.2 |
| Reference price 3 | 2.64 | 5.16 | 9.96 | 7.92 | 13.38 | 13.38 | 13.38 |
| Nbr of stocks (in thousands) | 3,483 | 9,399 | 13,818 | 15,459 | 20,831 | - | - |
| Announcement Date | 3/30/23 A | 3/27/24 A | 3/26/25 A | 3/27/26 A | - | - | - |
1CAD in Million2USD in Million3CAD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.14x | - | -6.54x | - | 201M | |
| 20.97x | 7.34x | 14.96x | 1.41% | 70.07B | |
| 30.34x | 7.64x | 23.38x | 0.05% | 52.87B | |
| -78.21x | 14.61x | -74.55x | -.--% | 27.02B | |
| 29.96x | 5.86x | 15.52x | -.--% | 23.61B | |
| -14.6x | 5.15x | -6.71x | -.--% | 23.38B | |
| 60.41x | 21.44x | 43.75x | 0.06% | 19.43B | |
| 25.59x | 4.85x | 16.27x | -.--% | 18.75B | |
| -802.92x | 37.67x | -14929.22x | -.--% | 15.85B | |
| 15.89x | 4.68x | 10.93x | -.--% | 12.7B | |
| Average | -71.67x | 12.14x | -1,489.22x | 0.17% | 26.39B | |
| Weighted average by Cap. | -36.19x | 10.37x | -890.23x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MSCL Stock
- Valuation Satellos Bioscience Inc.
Select your edition
All financial news and data tailored to specific country editions
